Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus in Refractory Rheumatoid Arthritis
ChiCTR-IPR-17011566Phase 4Recruiting
- Sponsor
- The Second Hospital of Shanxi Medical University
- Start
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of sirolimus in Refractory rheumatoid arthritis (RRA) (2 arms), sponsored by The Second Hospital of Shanxi Medical University. Primary endpoints: Peripheral blood lymphocyte subsets, CD4+ T-cell subgroups and 1 more. Started Jul 2017; status: recruiting.
02
Drugs
sirolimus
03
Conditions
Refractory rheumatoid arthritis (RRA)
Beyond the preview
Go deeper on ChiCTR-IPR-17011566.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR-IPR-17011566.